MedPath
HSA Approval

HYDROCHLORZIDE-50 TABLET 50 mg

SIN01561P

HYDROCHLORZIDE-50 TABLET 50 mg

HYDROCHLORZIDE-50 TABLET 50 mg

May 27, 1988

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAPEX PHARMA MARKETING PTE. LTD.
Licence HolderAPEX PHARMA MARKETING PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

**DOSAGE AND ADMINISTRATION** To be administered orally. ADULTS: Oedema : Usually, 25mg to 100mg once or twice daily or intermittently to a maximum of 200mg daily. Hypertension : 25mg to 50mg daily; either alone or in conjunction with other antihypertensive agents, to a maximum of 100mg daily. CHILDREN Usually 2.5mg per kg body weight a day, given in two doses.

ORAL

Medical Information

**INDICATIONS** **Hydrochlorzide** is indicated for the treatment of oedema and hypertension.

**CONTRAINDICATIONS** Anuria, known hypersensitivity to this product or to other sulphonamides-derived drugs.

C03AA03

hydrochlorothiazide

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

HYDROCHLOROTHIAZIDE

50 mg

Hydrochlorothiazide

Documents

Package Inserts

Hydrochlorzide-50 PI.pdf

Approved: February 10, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

HYDROCHLORZIDE-50 TABLET 50 mg - HSA Approval | MedPath